Lebrikizumab in Combination with Topical Corticosteroids Improves Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trial (ADhere)